No development-stage or early clinical trial-stage biotech has revenues. When you see people screaming about no revenues in an early-stage biotech like AVXL, either they don't understand how these companies develop, or they are trying to scare investors into selling.

I currently have NO POSITION in AVXL because I have doubts about the way the company does its business and runs its clinical trials.

However, people should do their own due diligence and not be scared by bashers.